YK-11 vs Oxandrolone

YK-11 (F-tier) vs Oxandrolone (S-tier). mechanism, trials, claims vs data, dosing literature. side-by-side reference.

YK-11 — tier F

a steroidal androgen-receptor research chemical with cell and animal findings, no controlled human trial, no measured half-life, and no established human safety margin.

the androgen-receptor signal is real in cells, but the human evidence file is empty and the safety file contains unresolved animal toxicity and case-level warning signals.

0 controlled human trials · half-life unknown; no measured concentration-time half-life in humans or animals · androgens

Oxandrolone — tier S

an oral 17-alpha-alkylated androgen with measured human pharmacokinetics and controlled burn data, whose US approvals were withdrawn in 2023 after FDA safety and effectiveness review.

the burn outcome and human half-life are real, and so are the withdrawal, boxed liver warning, lipid injury, and endocrine risks.

31.6 vs 43.3 days hospital stay in one severe-burn RCT · half-life 10.4 hours in younger volunteers and 13.3 hours in older adults in the historical Oxandrin label · androgens

at a glance

• YK-11: tier F · 0 controlled human trials
• Oxandrolone: tier S · 31.6 vs 43.3 days hospital stay in one severe-burn RCT

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.